The increasing number of applications filed for reimbursement decisions on the use of ultra-high-priced new drugs, such as ‘Zolgensma’ and ‘Keytruda’ that cost 2.5 billion won and 500 million won per shot, respectively, has upped the National Assembly’s demand for the improvement of the Risk-sharing Agreement system (RSA) and prior authorization system.

The Health Insurance Review and Assessment Service, which is in charge of the first step to reimbursement, has expressed its position that it will continue to work to determine a reasonable price for drugs and improve the patients’ accessibility to such drugs.

At the written responses provided by HIRA after the NA Health an